|Application ||WB, E|
|Calculated MW||47351 Da|
|Antigen Region||305-336 aa|
|Other Names||Carboxypeptidase A4, 3417-, Carboxypeptidase A3, CPA4, CPA3|
|Target/Specificity||This CPA4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 305-336 amino acids from the C-terminal region of human CPA4.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CPA4 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Metalloprotease that could be involved in the histone hyperacetylation pathway (PubMed:10383164). Releases a C-terminal amino acid, with preference for -Phe, -Leu, -Ile, -Met, -Tyr and -Val (PubMed:20385563).|
|Tissue Location||Fetal expression in the adrenal gland, brain, heart, intestine, kidney, liver and lung. Except for fetal brain that shows no imprinting, expression was found preferentially from the maternal allele|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CPA4 is a member of the carboxypeptidase A/B subfamily. Carboxypeptidases are zinc-containing exopeptidases that catalyze the release of carboxy-terminal amino acids, and are synthesized as zymogens that are activated by proteolytic cleavage. This protein could be involved in the histone hyperacetylation pathway. It is imprinted and may be a strong candidate protein for prostate cancer aggressiveness.
Ross,P.L., Cheng,I. BMC Cancer 9, 69 (2009)
Bentley,L., Nakabayashi,K. J. Med. Genet. 40 (4), 249-256 (2003)
Kayashima,T., Yamasaki,K. Hum. Genet. 112 (3), 220-226 (2003)
Hayashida,S., Yamasaki,K. Genomics 66 (2), 221-225 (2000)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.